Literature DB >> 24953558

miR-92a regulates TGF-β1-induced WISP1 expression in pulmonary fibrosis.

Barbara Berschneider1, Daniel C Ellwanger2, Hoeke A Baarsma1, Cedric Thiel1, Chiko Shimbori3, Eric S White4, Martin Kolb3, Peter Neth5, Melanie Königshoff6.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is the most common and fatal form of idiopathic interstitial pneumonia. MicroRNAs (miRNAs), short, single-stranded RNAs that regulate protein expression in a post-transcriptional manner, have recently been demonstrated to contribute to IPF pathogenesis. We have previously identified WNT1-inducible signaling pathway protein 1 (WISP1) as a highly expressed pro-fibrotic mediator in IPF, but the underlying mechanisms resulting in increased WISP1 expression, remain elusive. Here, we investigated whether WISP1 is a target of miRNA regulation. We applied a novel supervised machine learning approach, which predicted miR-30a/d and miR-92a target sites in regions of the human WISP1 3'UTR preferentially bound by the miRNA ribonucleoprotein complex. Both miRNAs were decreased in IPF samples, whereas WISP1 protein was increased. We demonstrated further that transforming growth factor (TGF)-β1-induced WISP1 expression in primary lung fibroblasts in vitro and lung homogenates in vivo. Notably, miR-30a and miR-92a reversed TGF-β1-induced WISP1 mRNA expression in lung fibroblasts. Moreover, miR-92a inhibition increased WISP1 protein expression in lung fibroblasts. An inverse relationship for WISP1 and miR-92a was found in a TGF-β1 dependent lung fibrosis model in vivo. Finally, we found significantly increased WISP1 expression in primary IPF fibroblasts, which negatively correlated with miR-92a level ex vivo. Altogether, our findings indicate a regulatory role of miR-92a for WISP1 expression in pulmonary fibrosis.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CCN4; Pulmonary fibrosis; WISP1; miR-30; miR-92a

Mesh:

Substances:

Year:  2014        PMID: 24953558     DOI: 10.1016/j.biocel.2014.06.011

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  38 in total

1.  Metformin attenuates TGF-β1-induced pulmonary fibrosis through inhibition of transglutaminase 2 and subsequent TGF-β pathways.

Authors:  Yubo Wang; Caiyu Lin; Rui Han; Conghua Lu; Li Li; Chen Hu; Mingxia Feng; Hengyi Chen; Yong He
Journal:  3 Biotech       Date:  2020-06-03       Impact factor: 2.406

2.  Upregulated has-miR-4516 as a potential biomarker for early diagnosis of dust-induced pulmonary fibrosis in patients with pneumoconiosis.

Authors:  Ruixue Huang; Ting Yu; Ying Li; Jianan Hu
Journal:  Toxicol Res (Camb)       Date:  2018-02-08       Impact factor: 3.524

Review 3.  MicroRNAs in non-small cell lung cancer and idiopathic pulmonary fibrosis.

Authors:  Keiko Mizuno; Hiroko Mataki; Naohiko Seki; Tomohiro Kumamoto; Kazuto Kamikawaji; Hiromasa Inoue
Journal:  J Hum Genet       Date:  2016-08-04       Impact factor: 3.172

4.  Human induced pluripotent stem cell-derived extracellular vesicles reduce hepatic stellate cell activation and liver fibrosis.

Authors:  Davide Povero; Eva M Pinatel; Aleksandra Leszczynska; Nidhi P Goyal; Takahiro Nishio; Jihoon Kim; David Kneiber; Lucas de Araujo Horcel; Akiko Eguchi; Paulina M Ordonez; Tatiana Kisseleva; Ariel E Feldstein
Journal:  JCI Insight       Date:  2019-06-11

5.  Angiokine Wisp-1 is increased in myocardial infarction and regulates cardiac endothelial signaling.

Authors:  Lillianne H Wright; Daniel J Herr; Symone S Brown; Harinath Kasiganesan; Donald R Menick
Journal:  JCI Insight       Date:  2018-02-22

Review 6.  Sick fat: the good and the bad of old and new circulating markers of adipose tissue inflammation.

Authors:  I Barchetta; F A Cimini; G Ciccarelli; M G Baroni; M G Cavallo
Journal:  J Endocrinol Invest       Date:  2019-05-09       Impact factor: 4.256

Review 7.  Epigenetic targets for novel therapies of lung diseases.

Authors:  Brian S Comer; Mariam Ba; Cherie A Singer; William T Gerthoffer
Journal:  Pharmacol Ther       Date:  2014-11-15       Impact factor: 12.310

Review 8.  The code of non-coding RNAs in lung fibrosis.

Authors:  Huachun Cui; Na Xie; Victor J Thannickal; Gang Liu
Journal:  Cell Mol Life Sci       Date:  2015-05-31       Impact factor: 9.261

Review 9.  WISP1: Clinical insights for a proliferative and restorative member of the CCN family.

Authors:  Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2014       Impact factor: 1.990

10.  CCN4/WISP1 controls cutaneous wound healing by modulating proliferation, migration and ECM expression in dermal fibroblasts via α5β1 and TNFα.

Authors:  Mitsuaki Ono; Asuka Masaki; Azusa Maeda; Tina M Kilts; Emilio S Hara; Taishi Komori; Hai Pham; Takuo Kuboki; Marian F Young
Journal:  Matrix Biol       Date:  2018-01-10       Impact factor: 11.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.